Truist Securities Maintains Buy on Pfizer, Lowers Price Target to $62
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Robyn Karnauskas maintains a 'Buy' rating on Pfizer (NYSE:PFE) but lowers the price target from $64 to $62.
August 04, 2023 | 11:43 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Truist Securities maintains a 'Buy' rating on Pfizer but lowers the price target from $64 to $62.
While the 'Buy' rating is maintained, the lowering of the price target could indicate a potential slowdown in growth or a perceived overvaluation. However, the impact is likely to be neutral in the short term as the rating is still positive.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100